Marc Wilson Biography and Net Worth



Marc Wilson has served as our Chief Financial Officer since January 2018. Prior to Crinetics, Mr. Wilson was Vice President of Finance and Accounting and Chief Accounting Officer at Cidara Therapeutics, Inc., from September 2014 to January 2018. From 2010 to 2014, Mr. Wilson was Director of Accounting and Controller at Trius Therapeutics, until its acquisition by Cubist Pharmaceuticals. Prior to Trius, Mr. Wilson worked at Neurocrine Biosciences, Inc. from 2007 to 2010. Mr. Wilson began his career with PricewaterhouseCoopers LLP and is a certified public accountant.

Mr. Wilson earned a bachelor’s degree in Economics and Accounting from the College of the Holy Cross.

What is Marc Wilson's net worth?

The estimated net worth of Marc Wilson is at least $3.83 million as of September 26th, 2024. Mr. Wilson owns 111,092 shares of Crinetics Pharmaceuticals stock worth more than $3,833,785 as of March 26th. This net worth evaluation does not reflect any other assets that Mr. Wilson may own. Additionally, Mr. Wilson receives an annual salary of $642,250.00 as CFO at Crinetics Pharmaceuticals. Learn More about Marc Wilson's net worth.

How old is Marc Wilson?

Mr. Wilson is currently 45 years old. There are 5 older executives and no younger executives at Crinetics Pharmaceuticals. The oldest executive at Crinetics Pharmaceuticals is Dr. R. Scott Struthers Ph.D., Founder, President, CEO & Director, who is 61 years old. Learn More on Marc Wilson's age.

What is Marc Wilson's salary?

As the CFO of Crinetics Pharmaceuticals, Inc., Mr. Wilson earns $642,250.00 per year. There are 4 executives that earn more than Mr. Wilson. The highest earning executive at Crinetics Pharmaceuticals is Dr. R. Scott Struthers Ph.D., Founder, President, CEO & Director, who commands a salary of $978,340.00 per year. Learn More on Marc Wilson's salary.

How do I contact Marc Wilson?

The corporate mailing address for Mr. Wilson and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at ir@crinetics.com. Learn More on Marc Wilson's contact information.

Has Marc Wilson been buying or selling shares of Crinetics Pharmaceuticals?

Marc Wilson has not been actively trading shares of Crinetics Pharmaceuticals within the last three months. Most recently, Marc Wilson sold 25,000 shares of the business's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $51.11, for a transaction totalling $1,277,750.00. Following the completion of the sale, the chief financial officer now directly owns 111,092 shares of the company's stock, valued at $5,677,912.12. Learn More on Marc Wilson's trading history.

Who are Crinetics Pharmaceuticals' active insiders?

Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), James Hassard (Chief Commercial Officer), Jeff Knight (COO), Alan Krasner (Chief Endocrinologist), Ajay Madan (Insider), Stephanie Okey (Director), Dana Pizzuti (Chief Medical and Development Officer), Richard Struthers (CEO), Coelho Vivaldi (Director), and Marc Wilson (CFO). Learn More on Crinetics Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Crinetics Pharmaceuticals?

During the last year, insiders at the sold shares 27 times. They sold a total of 429,216 shares worth more than $20,665,037.89. The most recent insider tranaction occured on March, 19th when insider Dana Pizzuti sold 2,515 shares worth more than $86,013.00. Insiders at Crinetics Pharmaceuticals own 6.0% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.

Information on this page was last updated on 3/19/2025.

Marc Wilson Insider Trading History at Crinetics Pharmaceuticals

See Full Table

Marc Wilson Buying and Selling Activity at Crinetics Pharmaceuticals

This chart shows Marc Wilson's buying and selling at Crinetics Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals logo
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $34.51
Low: $32.90
High: $34.99

50 Day Range

MA: $36.10
Low: $32.30
High: $40.40

2 Week Range

Now: $34.51
Low: $31.84
High: $62.53

Volume

1,147,320 shs

Average Volume

814,778 shs

Market Capitalization

$3.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58